Frequent aspirin use has been associated with reduced ovarian cancer risk, but no study has comprehensively assessed this effect. In a recent cohort study (a longitudinal study that includes a group of people who share a defining clinical characteristic) involving 8,326 patients, clinical researchers assessed study-specific associations between frequent aspirin use (≥ 6 days/week) and ovarian cancer risk. Additionally, ovarian cancer risk factors (endometriosis, obesity, family history of breast/ovarian cancer, nulliparity, oral contraceptive use, and tubal ligation) were also incorporated.
Frequent aspirin use is associated with a lower ovarian cancer risk.
Overall, frequent aspirin use was associated with a 13% reduction in ovarian cancer risk. This study, the largest to-date on aspirin use and ovarian cancer, provides evidence that frequent aspirin use is associated with a lower ovarian cancer risk, prompting further study of chemoprevention (the use of drugs to reduce the risk of cancer) strategies with frequent aspirin use that could potentially benefit patients who are at higher risk for developing ovarian cancer.
About Women’s Cancer Research Foundation
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Laguna Beach, CA 92651
PH: (949) 642-5165
Follow Us On Social Media:
Comments